Residual risk and high-density lipoprotein cholesterol levels: Is there a relationship?

Reviews in Cardiovascular Medicine

Volumn 12, Issue 2, 2011, Pages

  Shah, Prediman K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; High density lipoprotein cholesterol; Statins

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROSIS; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; INTERVENTION STUDY; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; POST HOC ANALYSIS; PREDICTION; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 80055066410     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0565     Document Type: Review

References (17)

1. Baigent C, Keech A, Kearney PM, et al Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357.
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009. (Pubitemid 26338729)
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622. (Pubitemid 28248586)
8. LaRosa JC, Grundy SM, Waters DD, et al Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435 Epub 2005 Mar 8.
9. Pedersen TR, Faergeman O, Kastelein JJ, et al Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445. (Pubitemid 41627921)
10. Cannon CP, Braunwald E, McCabe CH, et al Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504. (Pubitemid 38477774)
11. Kearney PM, Blackwell L, Collins R, et al Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125.
12. Shah PK. High-density lipoprotein mimetics: focus on synthetic high-density lipoprotein. Am J Cardiol. 2007;100(11 suppl 1):S62-S67. (Pubitemid 350161786)
13. Shah PK. Emerging HDL-based therapies for atherothrombotic vascular disease. Curr Treat Options Cardiovasc Med. 2007;9:60-70. (Pubitemid 46578390)
14. Ridker PM, Genest J, Boekholdt SM, et al JUPITER Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333-339.
15. Ridker PM, Danielson E, Fonseca FA, et al JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
16. Ray KK, Cannon CP, Cairns R, et al. Prognostic utility of apoB/AI, total cholesterol/HDL, non- HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2009;29:424-430.
17. Barter P, Gotto AM, LaRosa JC, et al Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-1310. (Pubitemid 47481452)